Compare MTC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTC | IRWD |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.2M | 663.6M |
| IPO Year | 2018 | 2009 |
| Metric | MTC | IRWD |
|---|---|---|
| Price | $3.14 | $3.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 105.6K | ★ 2.0M |
| Earning Date | 12-13-2024 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $14.73 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $0.25 | $0.66 |
| 52 Week High | $9.10 | $5.78 |
| Indicator | MTC | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 48.48 |
| Support Level | $2.37 | $3.08 |
| Resistance Level | $3.49 | $3.95 |
| Average True Range (ATR) | 0.62 | 0.19 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 16.02 | 67.44 |
MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. The company offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future and HC Securities, and MM Global. The Gujia segment provides market data services and consulting services to customers in China; and MM Global segment operates as an introducing broker that clears all transactions through a clearing broker dealer and earns commission income.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.